VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

HEAT-Net 2021 | CSF biomarkers versus blood biomarkers for the early diagnosis of Alzheimer’s disease

Alberto Lleó, MD, PhD, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, expresses his confidence in the use of cerebrospinal fluid (CSF) biomarkers to diagnose Alzheimer’s disease (AD) compared to novel blood-based biomarkers, given the close proximity of CSF to the brain. Dr Lleó highlights the importance of an early confirmed diagnosis of AD due to the impact of the disease on the patient and their relatives. This interview took place at the Harvard European Alumni Training Network (HEAT-Net) 2021 congress.

Disclosures

Dr. Lleo has received fees for advisory board meetings from Fujirebio-Europe, Novartis, Roche Diagnostics, Otsuka Pharmaceutical, Nutricia, Zambón and Biogen, speaker honoraria from Lilly, Biogen, KRKA and Zambon and is co-author of a licensed patent on markers of synaptopathy in neurodegenerative diseases (Nº: EP18382175.0, PCT/EP2019/056535).